Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream of the farnesylated small G protein Rheb and synergisticall...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Karp, Judith E., Flatten, Karen, Feldman, Eric J., Greer, Jacqueline M., Loegering, David A., Ricklis, Rebecca M., Morris, Lawrence E., Ritchie, Ellen, Smith, B. Douglas, Ironside, Valerie, Talbott, Timothy, Roboz, Gail, Le, Son B., Meng, Xue Wei, Schneider, Paula A., Dai, Nga T., Adjei, Alex A., Gore, Steven D., Levis, Mark J., Wright, John J., Garrett-Mayer, Elizabeth, Kaufmann, Scott H.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2009
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2686135/
https://ncbi.nlm.nih.gov/pubmed/19109557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-08-172726
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires